Skip Navigation

Michael J. Vasconcelles, MD

Medical Oncology

Make an Appointment
Watch Video


  • Instructor in Medicine, Harvard Medical School


Clinical Interests

  • Hematologic malignancies
  • Thoracic oncology

Contact Information

  • Appointments877-332-4294 (new)
    617-632-6190 (established)
  • Office Phone Number617-632-6049
  • Fax617-632-5786


Dr. Vasconcelles received his MD from Northwestern University in 1989. He completed his postgraduate training in internal medicine at Beth Israel Hospital and in hematology-oncology at Brigham and Women's Hospital. He then taught at BWH until 1999, when he joined the DFCI staff in the Lowe Center for Thoracic Oncology.

Board Certification:

  • Hematology, 1996
  • Medical Oncology, 1998


  • Brigham and Women's Hospital, Hematology & Oncology


  • Beth Israel Hospital, Internal Medicine

Medical School:

  • Northwestern University Medical School


Novel Oncologic Therapeutics and Oxygen Sensing

Over the past 25 years, Dr. Vasconcelles’ research interests in oncology have primarily focused on areas within tumor biology broadly referred to as nononcogene addiction, and more recently the emerging area of immunooncology. Several years ago in the laboratory, we established a eukaryotic model system using Saccharomyces cerevisiae (Baker’s yeast) to better understand the adaptive response to low oxygen tension. We learned that changes in gene expression in yeast, in response to hypoxia, are similar to higher eukaryotes in several fundamental ways, suggesting potential conservation of oxygen-sensing pathways.  

More recently, focus has turned to the development of novel cancer therapeutics based upon important discoveries and observations from several laboratories. Clinical research efforts have led to the development and approval of novel cancer medicines to treat chronic lymphocytic leukemia, pediatric acute lymphoblastic leukemia, Hodgkins’ lymphoma and anaplastic large cell lymphoma, mantle cell lymphoma, and multiple myeloma.  

Currently, our work is directed toward the development of genetically modified autologous Tcell therapies in cancer, with potential broad applications across a variety of malignancies.

Our work has been published in peer-reviewed journals such as Eukaryotic Cell, Biology of Blood and Marrow Transplantation, Journal of Biological Chemistry, Molecular and Cellular Biology, Journal of Clinical Oncology, among others.


Dana-Farber Cancer Institute
450 Brookline Avenue
Dana 1234
Boston, MA 02215
Get Directions